Galapagos (GLPG) said that its investigational CD19 CAR T-cell therapy, GLPG5101, has demonstrated "encouraging safety outcomes" in patients with relapsed non-Hodgkin's lymphoma, including low rates of high-grade toxicities.

Of the 64 patients enrolled, 95% received fresh, non-cryopreserved GLPG5101 without requiring cytotoxic bridging therapy, findings from the phase 1/2 study showed, Galapagos said Thursday in a statement.

Galapagos plans to present the data at the 30th European Hematology Association Congress.